Department of Radiation Oncology and the Case Integrative Cancer Biology Program, Case Comprehensive Cancer Center, University Hospitals Case Medical Center and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Clin Cancer Res. 2009 Nov 15;15(22):6912-20. doi: 10.1158/1078-0432.CCR-09-1698. Epub 2009 Oct 27.
MLH1 is a key DNA mismatch repair (MMR) protein involved in maintaining genomic stability by participating in the repair of endogenous and exogenous mispairs in the daughter strands during S phase. Exogenous mispairs can result following treatment with several classes of chemotherapeutic drugs, as well as with ionizing radiation. In this study, we investigated the role of the MLH1 protein in determining the cellular and molecular responses to prolonged low-dose rate ionizing radiation (LDR-IR), which is similar to the clinical use of cancer brachytherapy.
An isogenic pair of MMR(+) (MLH1(+)) and MMR(-) (MLH1(-)) human colorectal cancer HCT116 cells was exposed to prolonged LDR-IR (1.3-17 cGy/h x 24-96 h). The clonogenic survival and gene mutation rates were examined. Cell cycle distribution was analyzed with flow cytometry. Changes in selected DNA damage repair proteins, DNA damage response proteins, and cell death marker proteins were examined with Western blotting.
MLH1(+) HCT116 cells showed greater radiosensitivity with enhanced expression of apoptotic and autophagic markers, a reduced HPRT gene mutation rate, and more pronounced cell cycle alterations (increased late-S population and a G(2)/M arrest) following LDR-IR compared with MLH1(-) HCT116 cells. Importantly, a progressive increase in MLH1 protein levels was found in MLH1(+) cells during prolonged LDR-IR, which was temporally correlated with a progressive decrease in Rad51 protein (involved in homologous recombination) levels.
MLH1 status significantly affects cellular responses to prolonged LDR-IR. MLH1 may enhance cell radiosensitivity to prolonged LDR-IR through inhibition of homologous recombination (through inhibition of Rad51).
MLH1 是关键的 DNA 错配修复(MMR)蛋白,通过参与 S 期女儿链中外源和内源错配的修复,参与维持基因组稳定性。在外源错配中,可以在几种化疗药物以及电离辐射处理后发生。在这项研究中,我们研究了 MLH1 蛋白在确定细胞和分子对延长低剂量率电离辐射(LDR-IR)的反应中的作用,LDR-IR 类似于癌症近距离放射治疗的临床应用。
利用同源配对的 MMR(+)(MLH1(+))和 MMR(-)(MLH1(-))人结直肠癌细胞 HCT116 进行延长 LDR-IR(1.3-17 cGy/h x 24-96 h)处理。检测集落形成能力和基因突变率。利用流式细胞术分析细胞周期分布。用 Western blot 检测选定的 DNA 损伤修复蛋白、DNA 损伤反应蛋白和细胞死亡标记蛋白的变化。
与 MLH1(-) HCT116 细胞相比,MLH1(+) HCT116 细胞在 LDR-IR 后显示出更高的放射敏感性,表现为凋亡和自噬标志物表达增强、HPRT 基因突变率降低以及更明显的细胞周期改变(晚期 S 期细胞增多和 G2/M 期阻滞)。重要的是,在延长的 LDR-IR 过程中,MLH1(+) 细胞中的 MLH1 蛋白水平逐渐增加,与同源重组(涉及 Rad51 蛋白)水平的逐渐降低呈时间相关性。
MLH1 状态显著影响细胞对延长 LDR-IR 的反应。MLH1 可能通过抑制同源重组(通过抑制 Rad51)增强细胞对延长 LDR-IR 的放射敏感性。